Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
28.75
-0.64 (-2.18%)
At close: Aug 26, 2026, 4:00 PM EDT
28.50
-0.25 (-0.87%)
Pre-market: Aug 27, 2026, 5:35 AM EDT
Immunome Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Immunome stock has a consensus rating of "Strong Buy" and an average price target of $36.31. The average 1-year stock price forecast is 26.30% higher than the current stock price, while the lowest is $30 (+4.35%) and the highest is $40 (+39.13%).
Price Target: $36.31 (+26.30%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Immunome stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 11 | 11 | 11 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 15 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Buy Maintains $35 | Buy | Maintains | $35 | +21.74% | Aug 13, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Buy Maintains $31 → $35 | Buy | Maintains | $31 → $35 | +21.74% | Aug 12, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $40 | Buy | Maintains | $40 | +39.13% | Aug 12, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains $36 | Buy | Maintains | $36 | +25.22% | Aug 12, 2026 |
| Truist Financial | Truist Financial | Buy Maintains $37 → $38 | Buy | Maintains | $37 → $38 | +32.17% | Aug 12, 2026 |
Financial Forecast
Revenue This Year
333.33K
from 6.94M
Decreased by -95.20%
Revenue Next Year
55.56M
from 333.33K
Increased by 16,567.67%
EPS This Year
-2.31
from -2.43
EPS Next Year
-2.48
from -2.31
EPS and Forward PE are based on non-GAAP adjusted numbers.